Which patients is sparsentan suitable for?

Sparsentinis a drug used to treat adults with primary immunoglobulin A nephropathy, a disease in which the kidneys gradually stop working and eventually fail, requiring patients to undergo dialysis (a process that removes unwanted substances or excess fluid from the blood) or a kidney transplant. Primary means the cause of the disease is unknown.

Sparsentan is particularly indicated for adults who are at risk for rapid disease progressionIgAN. Specifically, the drug is particularly effective when the patient's urine protein to creatinine ratio (UPCR) reaches or exceeds 1.5 g/g. This is because high proteinuria levels are an important sign of worsening kidney disease, and sparsentane protects kidney function and delays disease progression by reducing proteinuria.

Clinical trial data further support the suitability of sparsentan. In a pivotal study, sparsentane significantly reduced proteinuria and improved kidney function in patients compared with placebo. More importantly, the safety of sparsentan has also been verified and will not cause systemic immunosuppressive effects, which reduces the risk of side effects such as infection.

However, although sparsentane works well in treatingIgAN, that does not mean it will work for all patients with kidney disease. Its efficacy is mainly targeted at primary immunoglobulin A nephropathy and does not cover other types of kidney diseases, such as diabetic nephropathy. Therefore, before use, doctors need to conduct a detailed evaluation of the patient to ensure that they are suitable for sparsentan treatment.

Overall, sparsentan is an effective treatment for patients with primary immunoglobulinA nephropathy, particularly those at risk for rapid disease progression and with high levels of proteinuria. By reducing proteinuria, it aims to protect kidney function and slow down disease progression, providing patients with new treatment options.

xa0

Reference link:https://www.ema.europa.eu/en/medicines/human/EPAR/filspari